Advertisement
Advertisement
HAE
Haemonetics Corporation
60.09
USDSponsored
+0.39
+0.65%
Mar 17, 16:00 UTC -4
Closed
After-Market
60.08
-0.01
-0.02%
HAE Earnings Reports
Positive Surprise Ratio
HAE beat 34 of 40 last estimates.
85%
Next Report
Date of Next Report
May 06, 2026
Estimate for Q4 26 (Revenue/ EPS)
$340.41M
/$1.28
Implied change from Q3 26 (Revenue/ EPS)
+0.43%
/-2.29%
Implied change from Q4 25 (Revenue/ EPS)
+2.97%
/+3.23%
Haemonetics Corporation earnings per share and revenue
On Feb 05, 2026, HAE reported earnings of 1.31 USD per share (EPS) for Q3 26, beating the estimate of 1.26 USD, resulting in a 3.75% surprise. Revenue reached 338.97 million, compared to an expected 334.93 million, with a 1.20% difference. The market reacted with a -1.41% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 12 analysts forecast an EPS of 1.28 USD, with revenue projected to reach 340.41 million USD, implying an decrease of -2.29% EPS, and increase of 0.43% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
BillionToOne, Inc. Class A Common Stock
Report Date
Mar 04, 2026 For Q4 25
Estimate
$0.08
Actual
$0.11
Surprise
+27.02%
Capricor Therapeutics Inc
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.55
Actual
-$0.62
Surprise
-12.56%
Brainsway Ltd. - ADR
Report Date
Mar 11, 2026 For Q4 25
Estimate
$0.13
Actual
$0.26
Surprise
+98.02%
Sundial Growers Inc. Common Shares
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.01
Actual
$0.04
Surprise
+499.62%
Viemed Healthcare, Inc. Common Shares
Report Date
Mar 04, 2026 For Q4 25
Estimate
$0.12
Actual
$0.14
Surprise
+10.85%
Apyx Medical Corporation Common Stock
Report Date
Mar 10, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.03
Surprise
+48.63%
MacroGenics, Inc.
Report Date
Mar 09, 2026 For Q4 25
Estimate
-$0.29
Actual
-$0.23
Surprise
+22.40%
Biote Corp. Class A Common Stock
Report Date
Mar 11, 2026 For Q4 25
Estimate
$0.05
Actual
$0.06
Surprise
+17.65%
Exagen Inc. Common Stock
Report Date
Mar 10, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.20
Surprise
-4.22%
Nephros Inc.
Report Date
Mar 12, 2026 For Q4 25
Estimate
$0.01
Actual
$0.08
Surprise
+684.31%
FAQ
What were Haemonetics Corporation's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Haemonetics Corporation reported EPS of $1.31, beating estimates by 3.75%, and revenue of $338.97M, 1.2% above expectations.
How did the market react to Haemonetics Corporation's Q3 2026 earnings?
The stock price moved down -1.41%, changed from $65.95 before the earnings release to $65.02 the day after.
When is Haemonetics Corporation expected to report next?
The next earning report is scheduled for May 06, 2026.
What are the forecasts for Haemonetics Corporation's next earnings report?
Based on 12
analysts, Haemonetics Corporation is expected to report EPS of $1.28 and revenue of $340.41M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement